Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-08-22 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022年半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset information for the half-year period. It also includes shareholder information and notes on audit opinions and dividend plans. The document is about 2609 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which requires comprehensive financial data for a period shorter than a full fiscal year. It is not merely an announcement or a summary without data, nor is it a full annual report or other filing type. Therefore, the correct classification is IR with high confidence. H1 2022
2022-08-22 Chinese
关于注销静泉分公司的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the cancellation (注销) of a branch office (静泉分公司) of the company 新乡拓新药业股份有限公司. It includes details about the branch, the reason for cancellation, and a statement that the cancellation will not affect the company's business or financial statements. There is no financial data, no mention of annual or quarterly reports, no voting results, no management changes, no legal proceedings, or other report types. The document is a regulatory announcement about a corporate structural change. Given the content and length (626 characters), it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-18 Chinese
关于子公司签署募集资金三方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of a tripartite supervision agreement related to the management and use of funds raised from a company's initial public offering (IPO). It details the fundraising amount, the establishment of special accounts for the funds, and the supervisory roles of involved parties. The document references previous announcements and approvals but does not contain financial statements or detailed financial performance data. It is primarily a regulatory announcement about fundraising fund management and supervision agreements, not a financial report or earnings release. The document length is about 3,031 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it concerns fundraising activities and related agreements.
2022-08-01 Chinese
关于子公司阿兹夫定原料药相关情况的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (435 characters) from a company about its subsidiary's product status and regulatory approvals related to a pharmaceutical product. It includes no financial data, no detailed report, and no mention of a meeting or voting results. It is an operational update about product certification and production capacity. The document is not a financial report, earnings release, or management discussion. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product compliance and approvals without fitting other specific categories.
2022-07-26 Chinese
关于使用部分闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the progress of using part of idle raised funds for cash management. It details the amounts, types of financial products purchased, risk analysis, and control measures. The document is relatively short (2222 characters) and focuses on a specific financing activity related to the use of idle raised funds. It does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release. It is not a regulatory certification or legal proceeding. The content fits best with an update on company fundraising or capital structure activities, specifically the use of idle raised funds for cash management. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-07-14 Chinese
关于使用部分闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the use of idle raised funds for cash management and the maturity redemption of related financial products. It details amounts, dates, and returns of structured deposits purchased with idle funds. The document is short (2004 characters) and primarily provides an update on cash management activities related to fundraising proceeds. It does not contain financial statements, audit opinions, or detailed financial results. It is not a full financial report but an announcement about the use and redemption of funds. This fits best under Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including use of raised funds for cash management.
2022-07-05 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.